Tag: BRCA Mutations Treatment Industry

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Breast Cancer Gene (BRCA) Mutations Treatment Market Forecast: What Value Will The Market Reach By 2030?

The market size for breast cancer gene (brca) mutations treatment has experienced significant growth in recent years. This market is expected to expand from $5.01 billion in 2025 to $5.37 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.2%. The growth observed in the past can be attributed to several factors including limited awareness of brca mutations, restricted access to genetic testing services, a reliance on conventional chemotherapy, the increasing incidence of breast and ovarian cancer, and the gradual adoption of targeted therapies.

The breast cancer gene (brca) mutations treatment market size is anticipated to experience substantial growth over the next few years. It is projected to expand to $7 billion in 2030, driven by a compound annual growth rate (CAGR) of 6.9%. This expansion during the forecast period can be attributed to advancements in genomic sequencing technologies, the broader application of PARP inhibitor indications, increased investment in precision oncology, the rising adoption of combination therapies, and favorable reimbursement policies for genetic testing and targeted treatments. Key trends in the upcoming period include the growing uptake of genetic testing and early brca mutation screening, an increasing reliance on PARP inhibitors in targeted therapy, a stronger emphasis on preventive and risk-reduction treatment strategies, the continuous development of personalized and precision oncology approaches, and enhanced access to multimodal treatment options for brca-related cancers.

Get A Free Sample Report With In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27231&type=smp&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Breast Cancer Gene (BRCA) Mutations Treatment Market Growth Drivers: What’s Behind The Acceleration?

The breast cancer gene (BRCA) mutation treatment market is anticipated to grow as a result of the increasing need for targeted therapies. Targeted therapies are medical interventions designed to specifically attack cancer cells by concentrating on genetic mutations or proteins that contribute to cancer growth. The escalating demand for these therapies is primarily due to their effectiveness in specifically targeting disease-causing cells or molecules while causing minimal damage to healthy tissues, leading to better treatment outcomes and fewer side effects compared to conventional treatments. Targeted therapies aid in the treatment of breast cancer gene (BRCA) mutations by offering precise medications that specifically address the genetic alterations driving the disease, thereby improving treatment results and reducing unnecessary side effects. For instance, in July 2023, according to a report from the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, at the end of Q1 2023, there were 247 gene therapies in Phase II, which increased by 5% to reach 260 by the end of Q2 2023. Therefore, the growing demand for targeted therapies is propelling the expansion of the breast cancer gene (BRCA) mutation treatment market.

Breast Cancer Gene (BRCA) Mutations Treatment Market Segmentation: How Does The Market Break Down By Category?

The breast cancer gene (brca) mutations treatment market covered in this report is segmented –

1) By Treatment Type: Targeted Therapies, Chemotherapy, Hormonal Therapy, Immunotherapy

2) By Indication: Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer

3) By Administration Route: Oral, Intravenous, Subcutaneous

4) By End-User: Hospitals, Clinics, Cancer Specialty Clinics

Subsegments:

1) By Targeted Therapies: Poly (ADP-Ribose) Polymerase Inhibitors, Mammalian Target Of Rapamycin Inhibitors, Cyclin-Dependent Kinase 4 And 6 Inhibitors, Tyrosine Kinase Inhibitors

2) By Chemotherapy: Platinum-Based chemotherapy, Anthracyclines, Taxanes, Antimetabolites

3) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs), Luteinizing Hormone-Releasing Hormone (LHRH) Agonists

4) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Monoclonal Antibodies

Breast Cancer Gene (BRCA) Mutations Treatment Market Competitive Overview And Top Companies

Major companies operating in the breast cancer gene (brca) mutations treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Thermo Fisher Scientific Inc., AstraZeneca PLC, Novartis AG, GSK plc, Janssen Biotech Inc., Astellas Pharma Inc., Genentech Inc., Clovis Oncology Inc., Owkin Inc., Allarity Therapeutics Inc., VBL Therapeutics

View The Full Breast Cancer Gene (BRCA) Mutations Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/breast-cancer-gene-brca-mutations-treatment-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Breast Cancer Gene (BRCA) Mutations Treatment Market Largest Region: Which Geography Holds The Highest Market Share?

North America was the largest region in the breast cancer gene (BRCA) mutations treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer gene (brca) mutations treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Breast Cancer Gene (BRCA) Mutations Treatment Market Size And Revenue Forecast Through 2030

The market for treatments targeting breast cancer gene (BRCA) mutations has experienced robust expansion in recent years. Projected to rise from $5.01 billion in 2025 to $5.37 billion in 2026, this growth reflects a compound annual growth rate (CAGR) of 7.2%. Several factors drove progress during the historical period, including limited public understanding of BRCA mutations, constrained availability of genetic testing services, a continued dependence on traditional chemotherapy, a rising prevalence of breast and ovarian cancers, and the slow but steady uptake of targeted therapeutic approaches.

The market for treatments targeting BRCA gene mutations is projected to experience robust expansion over the coming years, reaching a valuation of $7 billion by 2030 with a compound annual growth rate (CAGR) of 6.9%. This anticipated growth during the forecast period is driven by progress in genomic sequencing technologies, the broadening of PARP inhibitor applications, heightened investment in precision oncology, a greater emphasis on combination therapies, and favorable reimbursement policies for genetic testing and targeted treatments. Key trends shaping this period include the increased uptake of genetic testing and early BRCA mutation screening, the widespread use of PARP inhibitors in targeted therapy, a stronger focus on preventive and risk-reduction treatment approaches, the advancement of personalized and precision oncology methods, and enhanced availability of multimodal treatment options for BRCA-related cancers.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27231&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Breast Cancer Gene (BRCA) Mutations Treatment Market Development Factors: Which Trends Are Supporting Demand?

The rising need for targeted therapies is anticipated to drive expansion in the breast cancer gene (BRCA) mutation treatment market moving forward. These therapies are medical approaches designed to precisely attack cancer cells by concentrating on genetic mutations or proteins involved in tumor growth. This growing demand stems largely from their capacity to specifically target disease-causing cells or molecules while sparing healthy tissues, leading to enhanced treatment efficacy and reduced side effects compared to conventional options. Targeted therapies aid in managing BRCA mutations by delivering precision medicines that directly address the genetic abnormalities fueling the disease, thereby improving outcomes and limiting unnecessary adverse effects. For example, in July 2023, a report from the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, indicated that at the close of Q1 2023, there were 247 gene therapies in Phase II, which increased by 5% to 260 by the end of Q2 2023. Consequently, the escalating demand for targeted therapies is fueling growth in the breast cancer gene (BRCA) mutation treatment market.

The increasing emphasis on personalised medicine is expected to boost the breast cancer gene (BRCA) mutation treatment market going forward. Personalised medicine involves customizing medical care to an individual’s distinct genetic, biological, and clinical profile. This trend is gaining momentum due to advancements in genetic testing, enabling treatments to be more accurately tailored to each person’s biological characteristics. A heightened focus on personalised medicine is reshaping the management of BRCA gene mutations by facilitating customized risk evaluation, targeted therapies like PARP inhibitors, and individualized prevention plans that maximize treatment effectiveness while reducing adverse effects, ultimately enhancing outcomes for patients with hereditary breast and ovarian cancers. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the FDA approved 16 new personalised treatments for rare disease patients, a rise from 6 in 2022. These newly approved treatments for 2023 also included seven cancer drugs and three for other diseases and conditions. Thus, the growing emphasis on personalised medicine is driving expansion in the breast cancer gene (BRCA) mutation treatment market.

Breast Cancer Gene (BRCA) Mutations Treatment Market Segment Breakdown: Which Categories Generate The Most Revenue?

The breast cancer gene (brca) mutations treatment market covered in this report is segmented –

1) By Treatment Type: Targeted Therapies, Chemotherapy, Hormonal Therapy, Immunotherapy

2) By Indication: Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer

3) By Administration Route: Oral, Intravenous, Subcutaneous

4) By End-User: Hospitals, Clinics, Cancer Specialty Clinics

Subsegments:

1) By Targeted Therapies: Poly (ADP-Ribose) Polymerase Inhibitors, Mammalian Target Of Rapamycin Inhibitors, Cyclin-Dependent Kinase 4 And 6 Inhibitors, Tyrosine Kinase Inhibitors

2) By Chemotherapy: Platinum-Based chemotherapy, Anthracyclines, Taxanes, Antimetabolites

3) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs), Luteinizing Hormone-Releasing Hormone (LHRH) Agonists

4) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Monoclonal Antibodies

Breast Cancer Gene (BRCA) Mutations Treatment Market Key Players And Strategic Industry Positioning

Major companies operating in the breast cancer gene (brca) mutations treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Thermo Fisher Scientific Inc., AstraZeneca PLC, Novartis AG, GSK plc, Janssen Biotech Inc., Astellas Pharma Inc., Genentech Inc., Clovis Oncology Inc., Owkin Inc., Allarity Therapeutics Inc., VBL Therapeutics

Access The Complete Breast Cancer Gene (BRCA) Mutations Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/breast-cancer-gene-brca-mutations-treatment-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Breast Cancer Gene (BRCA) Mutations Treatment Market Largest Region By Revenue And Market Share

North America was the largest region in the breast cancer gene (BRCA) mutations treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer gene (brca) mutations treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Size Of The Breast Cancer Gene (BRCA) Mutations Treatment Market Progress Through 2030?

The breast cancer gene (brca) mutations treatment market size has experienced robust growth in recent years. It is anticipated to increase from $5.01 billion in 2025 to $5.37 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.2%. The historical growth of this market can be attributed to several factors including limited awareness of brca mutations, restricted access to genetic testing services, a reliance on conventional chemotherapy, the increasing incidence of breast and ovarian cancer, and the gradual adoption of targeted therapies.

The breast cancer gene (brca) mutations treatment market is projected to experience substantial expansion over the coming years, reaching a valuation of $7 billion by 2030, driven by a compound annual growth rate (CAGR) of 6.9%. This anticipated growth is primarily fueled by breakthroughs in genomic sequencing technologies, the broadened applications of PARP inhibitors, increased financial commitments in precision oncology, a rise in the use of combination therapies, and favorable reimbursement policies for both genetic testing and targeted treatments. Key developments expected during this period involve a greater uptake of genetic testing and early screening for brca mutations, the increasing deployment of PARP inhibitors in targeted therapeutic approaches, an intensified focus on strategies for prevention and risk reduction, the broadening scope of personalized and precision oncology, and enhanced availability of diverse treatment options for brca-related cancers.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27231&type=smp

Which Core Factors Are Supporting The Expansion Of The Breast Cancer Gene (BRCA) Mutations Treatment Market?

The increasing emphasis on personalized medicine is anticipated to drive the expansion of the breast cancer gene (BRCA) mutation treatment market in the coming years. Personalized medicine involves customizing medical treatments based on a person’s distinct genetic, biological, and clinical profile. This advancement in personalized medicine is propelled by improvements in genetic testing, enabling more precise treatment customization according to each individual’s biological composition. A heightened focus on personalized medicine is revolutionizing the approach to BRCA gene mutations, facilitating personalized risk assessments, the use of targeted therapies like PARP inhibitors, and customized preventive measures. These strategies enhance treatment effectiveness, reduce side effects, and ultimately improve results for individuals with hereditary breast and ovarian cancers. As an illustration, the Personalized Medicine Coalition, a US-based non-profit organization, reported in February 2024 that the FDA approved 16 new personalized treatments for rare disease patients in 2023, a significant rise from 6 approvals in 2022. Among the personalized treatments newly approved in 2023 were also seven cancer drugs and three for various other diseases and conditions. Thus, the increasing attention on personalized medicine is a key factor propelling the growth of the breast cancer gene (BRCA) mutation treatment market.

Which Segment-Based Categories Are Covered In The Breast Cancer Gene (BRCA) Mutations Treatment Market?

The breast cancer gene (brca) mutations treatment market covered in this report is segmented –

1) By Treatment Type: Targeted Therapies, Chemotherapy, Hormonal Therapy, Immunotherapy

2) By Indication: Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer

3) By Administration Route: Oral, Intravenous, Subcutaneous

4) By End-User: Hospitals, Clinics, Cancer Specialty Clinics

Subsegments:

1) By Targeted Therapies: Poly (ADP-Ribose) Polymerase Inhibitors, Mammalian Target Of Rapamycin Inhibitors, Cyclin-Dependent Kinase 4 And 6 Inhibitors, Tyrosine Kinase Inhibitors

2) By Chemotherapy: Platinum-Based chemotherapy, Anthracyclines, Taxanes, Antimetabolites

3) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs), Luteinizing Hormone-Releasing Hormone (LHRH) Agonists

4) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Monoclonal Antibodies

Who Are The Companies Shaping The Breast Cancer Gene (BRCA) Mutations Treatment Market Landscape?

Major companies operating in the breast cancer gene (brca) mutations treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Thermo Fisher Scientific Inc., AstraZeneca PLC, Novartis AG, GSK plc, Janssen Biotech Inc., Astellas Pharma Inc., Genentech Inc., Clovis Oncology Inc., Owkin Inc., Allarity Therapeutics Inc., VBL Therapeutics

Access The Complete Breast Cancer Gene (BRCA) Mutations Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/breast-cancer-gene-brca-mutations-treatment-global-market-report

Which Area Represents The Largest Portion Of The Breast Cancer Gene (BRCA) Mutations Treatment Market?

North America was the largest region in the breast cancer gene (BRCA) mutations treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer gene (brca) mutations treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Breast Cancer Gene (BRCA) Mutations Treatment Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=27231&type=smp

Browse Through More Reports Similar to the Global Breast Cancer Gene (BRCA) Mutations Treatment Market 2026, By The Business Research Company

Converted Paper Products Market Report 2026

https://www.thebusinessresearchcompany.com/report/converted-paper-products-global-market-report

Decorative Concrete Market Report 2026

https://www.thebusinessresearchcompany.com/report/decorative-concrete-global-market-report

Concrete Materials Market Report 2026

https://www.thebusinessresearchcompany.com/report/concrete-materials-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Level Of Market Value Growth Is Predicted For The Breast Cancer Gene (BRCA) Mutations Treatment Market From 2026 To 2030?

The breast cancer gene (brca) mutations treatment market has demonstrated robust expansion in recent years. This market is projected to increase from $5.01 billion in 2025 to $5.37 billion in 2026, growing at a compound annual growth rate (CAGR) of 7.2%. During the historic period, this growth was influenced by factors such as limited awareness of brca mutations, restricted access to genetic testing services, a reliance on conventional chemotherapy, the increasing incidence of breast and ovarian cancer, and the gradual adoption of targeted therapies.

The breast cancer gene (brca) mutations treatment market size anticipates substantial expansion over the upcoming years. This market is projected to reach $7 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.9%. This anticipated growth during the forecast period is largely driven by strides in genomic sequencing technologies, broader applications for PARP inhibitors, escalating investments in precision oncology, a surge in the use of combination therapies, and favorable reimbursement policies supporting genetic testing and targeted treatments. Key trends shaping the forecast period encompass an uptick in the embrace of genetic testing and early BRCA mutation screening, the increasing application of PARP inhibitors within targeted therapies, a heightened emphasis on preventive and risk-reduction treatment strategies, the broadening of personalized and precision oncology methods, and enhanced availability of diverse treatment options for BRCA-related cancers.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27231&type=smp

What Leading Drivers Are Supporting The Breast Cancer Gene (BRCA) Mutations Treatment Market Expansion?

A growing need for targeted therapies is projected to drive the expansion of the breast cancer gene (BRCA) mutation treatment market moving forward. These medical interventions specifically target cancer cells by focusing on genetic mutations or proteins crucial for cancer growth. The increasing adoption of targeted therapies is primarily due to their capability to precisely attack disease-causing cells or molecules while preserving healthy tissues, leading to better treatment outcomes and fewer side effects compared to conventional treatments. Targeted therapies enhance the treatment of breast cancer gene (BRCA) mutations by offering precision medicines that directly address the genetic alterations causing the disease, thereby improving patient results and minimizing unwanted side effects. For instance, in July 2023, according to the report published by the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, at the end of Q1 2023, there were 247 gene therapies in Phase II, this number rose by 5% and reached 260 by the end of Q2 2023. Thus, the rising demand for targeted therapies is propelling the growth of the breast cancer gene (BRCA) mutation treatment market.

How Is The Breast Cancer Gene (BRCA) Mutations Treatment Market Segmented Across Different Segment Categories?

The breast cancer gene (brca) mutations treatment market covered in this report is segmented –

1) By Treatment Type: Targeted Therapies, Chemotherapy, Hormonal Therapy, Immunotherapy

2) By Indication: Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer

3) By Administration Route: Oral, Intravenous, Subcutaneous

4) By End-User: Hospitals, Clinics, Cancer Specialty Clinics

Subsegments:

1) By Targeted Therapies: Poly (ADP-Ribose) Polymerase Inhibitors, Mammalian Target Of Rapamycin Inhibitors, Cyclin-Dependent Kinase 4 And 6 Inhibitors, Tyrosine Kinase Inhibitors

2) By Chemotherapy: Platinum-Based chemotherapy, Anthracyclines, Taxanes, Antimetabolites

3) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs), Luteinizing Hormone-Releasing Hormone (LHRH) Agonists

4) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Monoclonal Antibodies

Which Organizations Play A Role In The Breast Cancer Gene (BRCA) Mutations Treatment Market Landscape?

Major companies operating in the breast cancer gene (brca) mutations treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Thermo Fisher Scientific Inc., AstraZeneca PLC, Novartis AG, GSK plc, Janssen Biotech Inc., Astellas Pharma Inc., Genentech Inc., Clovis Oncology Inc., Owkin Inc., Allarity Therapeutics Inc., VBL Therapeutics

Get The Full Breast Cancer Gene (BRCA) Mutations Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/breast-cancer-gene-brca-mutations-treatment-global-market-report

Which Region Is The Largest In The Breast Cancer Gene (BRCA) Mutations Treatment Market?

North America was the largest region in the breast cancer gene (BRCA) mutations treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer gene (brca) mutations treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Breast Cancer Gene (BRCA) Mutations Treatment Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/breast-cancer-gene-brca-mutations-treatment-global-market-report

Browse Through More Reports Similar to the Global Breast Cancer Gene (BRCA) Mutations Treatment Market 2026, By The Business Research Company

Converted Paper Products Market Report 2026

https://www.thebusinessresearchcompany.com/report/converted-paper-products-global-market-report

Decorative Concrete Market Report 2026

https://www.thebusinessresearchcompany.com/report/decorative-concrete-global-market-report

Concrete Materials Market Report 2026

https://www.thebusinessresearchcompany.com/report/concrete-materials-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Breast Cancer Gene (BRCA) Mutations Treatment Market Expected To Change Between 2026 And 2030?

The breast cancer gene (brca) mutations treatment market size has witnessed robust growth over recent years. It is projected to expand from $5.01 billion in 2025 to $5.37 billion in 2026, at a compound annual growth rate (CAGR) of 7.2%. The increase observed in previous periods is attributable to factors such as limited awareness of brca mutations, restricted availability of genetic testing services, a continued reliance on conventional chemotherapy, the rising incidence of breast and ovarian cancer, and the progressive adoption of targeted therapies.

The breast cancer gene (brca) mutations treatment market size is anticipated to demonstrate significant growth over the next few years. It is projected to expand to $7 billion by 2030, achieving a compound annual growth rate (CAGR) of 6.9%. This growth throughout the forecast period can be attributed to several factors, including advancements in genomic sequencing technologies, an increase in PARP inhibitor indications, rising investment in precision oncology, greater adoption of combination therapies, and supportive reimbursement policies for genetic testing and targeted treatments. Major trends expected during this period include a rising uptake of genetic testing and early BRCA mutation screening, the growing utilization of PARP inhibitors in targeted therapy, an increasing focus on preventive and risk-reduction treatment strategies, the expansion of personalized and precision oncology approaches, and improved access to multimodal treatment options for BRCA-related cancers.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27231&type=smp

What Underlying Factors Are Accelerating The Growth Of The Breast Cancer Gene (BRCA) Mutations Treatment Market?

The heightened need for targeted therapies is anticipated to drive the expansion of the breast cancer gene (BRCA) mutation treatment market in the future. These therapies are medical interventions designed to precisely target cancer cells by concentrating on genetic alterations or specific proteins crucial for cancer development. The growing preference for targeted therapies stems mainly from their capacity to specifically attack diseased cells or molecules, thereby reducing harm to healthy tissues, which leads to enhanced treatment efficacy and fewer adverse reactions compared to conventional treatments. For breast cancer gene (BRCA) mutations, targeted therapies are beneficial as they provide precision medications that specifically tackle the genetic changes causing the illness, thereby improving patient results and lessening unwanted side effects. For example, in July 2023, a report from the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership body, indicated that there were 247 gene therapies in Phase II at the close of Q1 2023. This figure increased by 5%, reaching 260 by the end of Q2 2023. Consequently, the escalating demand for targeted therapies is propelling the expansion of the breast cancer gene (BRCA) mutation treatment market. An increasing emphasis on personalized medicine is projected to stimulate the growth of the breast cancer gene (BRCA) mutation treatment market moving ahead. Personalized medicine involves customizing medical care to match a patient’s distinct genetic, biological, and clinical attributes. The expansion of personalized medicine is fueled by progress in genetic testing, enabling treatments to be more accurately customized to each person’s biological profile. The heightened focus on personalized medicine is revolutionizing how BRCA gene mutations are managed. This is achieved by facilitating customized risk assessments, specific therapies like PARP inhibitors, and individual preventive approaches that maximize treatment effectiveness while reducing negative side effects, thereby ultimately enhancing results for patients suffering from hereditary breast and ovarian cancers. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, an increase from 6 in 2022. Among these newly approved personalized treatments for 2023 were seven cancer drugs and three for other diseases and conditions. Consequently, the increasing emphasis on personalized medicine is a key driver for the growth of the breast cancer gene (BRCA) mutation treatment market.

How Is The Breast Cancer Gene (BRCA) Mutations Treatment Market Structured Across Different Segments?

The breast cancer gene (brca) mutations treatment market covered in this report is segmented –

1) By Treatment Type: Targeted Therapies, Chemotherapy, Hormonal Therapy, Immunotherapy

2) By Indication: Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer

3) By Administration Route: Oral, Intravenous, Subcutaneous

4) By End-User: Hospitals, Clinics, Cancer Specialty Clinics

Subsegments:

1) By Targeted Therapies: Poly (ADP-Ribose) Polymerase Inhibitors, Mammalian Target Of Rapamycin Inhibitors, Cyclin-Dependent Kinase 4 And 6 Inhibitors, Tyrosine Kinase Inhibitors

2) By Chemotherapy: Platinum-Based chemotherapy, Anthracyclines, Taxanes, Antimetabolites

3) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs), Luteinizing Hormone-Releasing Hormone (LHRH) Agonists

4) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Monoclonal Antibodies

Which Major Players Dominate The Breast Cancer Gene (BRCA) Mutations Treatment Market?

Major companies operating in the breast cancer gene (brca) mutations treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Thermo Fisher Scientific Inc., AstraZeneca PLC, Novartis AG, GSK plc, Janssen Biotech Inc., Astellas Pharma Inc., Genentech Inc., Clovis Oncology Inc., Owkin Inc., Allarity Therapeutics Inc., VBL Therapeutics

Read the full breast cancer gene (brca) mutations treatment market report here:

https://www.thebusinessresearchcompany.com/report/breast-cancer-gene-brca-mutations-treatment-global-market-report

Which Region Is Projected To Dominate The Breast Cancer Gene (BRCA) Mutations Treatment Market During The Forecast Period?

North America was the largest region in the breast cancer gene (BRCA) mutations treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer gene (brca) mutations treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Breast Cancer Gene (BRCA) Mutations Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27231&type=smp

Browse Through More Reports Similar to the Global Breast Cancer Gene (BRCA) Mutations Treatment Market 2026, By The Business Research Company

Converted Paper Products Market Report 2026

https://www.thebusinessresearchcompany.com/report/converted-paper-products-global-market-report

Decorative Concrete Market Report 2026

https://www.thebusinessresearchcompany.com/report/decorative-concrete-global-market-report

Concrete Materials Market Report 2026

https://www.thebusinessresearchcompany.com/report/concrete-materials-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the breast cancer gene (brca) mutations treatment market from 2026–2035 with trusted insights from The Business Research Company

How much is the Breast Cancer Gene (BRCA) Mutations Treatment Market valued at in 2026, and what valuation is forecast for 2030?

The breast cancer gene (brca) mutations treatment market size has experienced significant growth in recent years. It is anticipated to increase from $5.01 billion in 2025 to $5.37 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.2%. The expansion observed in prior periods can be linked to factors like a scarcity of information concerning brca mutations, limited accessibility to genetic testing services, a reliance on traditional chemotherapy, an escalating occurrence of breast and ovarian cancer, and the progressive adoption of targeted therapies.

The market for treating breast cancer gene (brca) mutations is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of $7 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.9%. The anticipated growth during this period is attributable to several factors, including progress in genomic sequencing technologies, the broadened applications of parp inhibitor indications, increasing financial commitments to precision oncology, a rise in the use of combination therapies, and favorable reimbursement policies for both genetic testing and targeted treatments. Key trends expected over the forecast horizon encompass the increasing uptake of genetic testing and early brca mutation screening, an expanded role for parp inhibitors in targeted therapy, a heightened emphasis on preventive and risk-reduction treatment strategies, the proliferation of personalized and precision oncology methods, and enhanced availability of multimodal treatment options for brca-related cancers.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27231&type=smp

What Drivers Are Influencing The Growth Of The Breast Cancer Gene (BRCA) Mutations Treatment Market?

The growing need for targeted therapies is anticipated to boost the breast cancer gene (BRCA) mutation treatment market moving forward. Targeted therapies are medical interventions designed to precisely attack cancer cells by concentrating on genetic mutations or proteins contributing to cancer development. The increased preference for targeted therapies stems from their capacity to specifically target disease-causing cells or molecules, thereby reducing harm to healthy tissues. This leads to enhanced treatment efficacy and fewer adverse reactions compared to conventional treatments. Such therapies aid in managing breast cancer gene (BRCA) mutations by providing precision medicines that directly address the genetic changes driving the condition, thus improving treatment results and lessening unwanted side effects. For example, in July 2023, a report from the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, indicated that there were 247 gene therapies in Phase II at the end of Q1 2023. This figure saw a 5% increase, reaching 260 by the close of Q2 2023. Consequently, the rising demand for targeted therapies is propelling the expansion of the breast cancer gene (BRCA) mutation treatment market.

How Is The Breast Cancer Gene (BRCA) Mutations Treatment Market Organized Into Various Segments?

The breast cancer gene (brca) mutations treatment market covered in this report is segmented –

1) By Treatment Type: Targeted Therapies, Chemotherapy, Hormonal Therapy, Immunotherapy

2) By Indication: Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer

3) By Administration Route: Oral, Intravenous, Subcutaneous

4) By End-User: Hospitals, Clinics, Cancer Specialty Clinics

Subsegments:

1) By Targeted Therapies: Poly (ADP-Ribose) Polymerase Inhibitors, Mammalian Target Of Rapamycin Inhibitors, Cyclin-Dependent Kinase 4 And 6 Inhibitors, Tyrosine Kinase Inhibitors

2) By Chemotherapy: Platinum-Based chemotherapy, Anthracyclines, Taxanes, Antimetabolites

3) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs), Luteinizing Hormone-Releasing Hormone (LHRH) Agonists

4) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Monoclonal Antibodies

Who Are The Primary Competitors In The Global Breast Cancer Gene (BRCA) Mutations Treatment Market?

Major companies operating in the breast cancer gene (brca) mutations treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Thermo Fisher Scientific Inc., AstraZeneca PLC, Novartis AG, GSK plc, Janssen Biotech Inc., Astellas Pharma Inc., Genentech Inc., Clovis Oncology Inc., Owkin Inc., Allarity Therapeutics Inc., VBL Therapeutics

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/breast-cancer-gene-brca-mutations-treatment-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Breast Cancer Gene (BRCA) Mutations Treatment Market?

North America was the largest region in the breast cancer gene (BRCA) mutations treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer gene (brca) mutations treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Breast Cancer Gene (BRCA) Mutations Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27231&type=smp

Browse Through More Reports Similar to the Global Breast Cancer Gene (BRCA) Mutations Treatment Market 2026, By The Business Research Company

Converted Paper Products Market Report 2026

https://www.thebusinessresearchcompany.com/report/converted-paper-products-global-market-report

Decorative Concrete Market Report 2026

https://www.thebusinessresearchcompany.com/report/decorative-concrete-global-market-report

Concrete Materials Market Report 2026

https://www.thebusinessresearchcompany.com/report/concrete-materials-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the breast cancer gene (brca) mutations treatment market from 2025–2034 with trusted insights from The Business Research Company

What Are The Market Size Estimates For The Breast Cancer Gene (BRCA) Mutations Treatment Market?

The market for treating breast cancer gene (BRCA) mutations has shown significant growth in recent years. This market is projected to expand from $4.67 billion in 2024 to $5.01 billion by 2025, exhibiting a compound annual growth rate (CAGR) of 7.4%. Historically, this expansion has been driven by factors such as the increasing availability of genetic testing, augmented government and private investment in oncology research, a heightened demand for personalized medicine, the wider adoption of preventive healthcare strategies, and a rise in the number of at-risk individuals undergoing screening.

The breast cancer gene (BRCA) mutations treatment market size is projected to experience substantial growth in the upcoming years, expanding to $6.56 billion by 2029 at a compound annual growth rate (CAGR) of 7.0%. This anticipated growth is driven by increasing inclusion of genetic testing in insurance coverage, a growing demand for companion diagnostics, a rising focus on hereditary cancer screening programs, an increase in clinical trials targeting BRCA-related cancers, and the rising adoption of risk-reducing surgical procedures. Major trends expected during this period include advancements in gene editing technologies, innovations in non-invasive diagnostic techniques, the integration of AI and machine learning in genetic risk assessment, progress in liquid biopsy applications for BRCA-related cancers, and new developments in personalized treatment algorithms.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27231&type=smp

Which Industry Forces Are Driving The Breast Cancer Gene (BRCA) Mutations Treatment Market Forward?

The breast cancer gene (BRCA) mutation treatment market is anticipated to expand due to the escalating need for targeted therapies. These medical interventions specifically attack cancer cells by focusing on genetic mutations or proteins that fuel cancer development. The heightened demand for targeted therapies primarily stems from their capacity to precisely attack disease-causing cells or molecules, thereby reducing harm to healthy tissues, which leads to greater treatment efficacy and fewer adverse effects compared to conventional treatments. For breast cancer gene (BRCA) mutations, targeted therapies are beneficial as they provide precision medicines that directly tackle the genetic changes responsible for the illness, thereby enhancing treatment results and lessening unwanted side effects. An example of this trend is seen in data from July 2023: a report from the American Society of Gene & Cell Therapy (ASGCT), a professional US-based organization, indicated that there were 247 gene therapies in Phase II at the close of Q1 2023. This figure subsequently climbed by 5%, reaching 260 by the end of Q2 2023. Consequently, the growing need for targeted therapies is propelling the expansion of the breast cancer gene (BRCA) mutation treatment market.

How Is The Breast Cancer Gene (BRCA) Mutations Treatment Market Organized By Different Segments?

The breast cancer gene (BRCA) mutations treatment market covered in this report is segmented

1) By Treatment Type: Targeted Therapies, Chemotherapy, Hormonal Therapy, Immunotherapy

2) By Indication: Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer

3) By Administration Route: Oral, Intravenous, Subcutaneous

4) By End-User: Hospitals, Clinics, Cancer Specialty Clinics

Subsegments:

1) By Targeted Therapies: Poly (ADP-Ribose) Polymerase Inhibitors, Mammalian Target Of Rapamycin Inhibitors, Cyclin-Dependent Kinase 4 And 6 Inhibitors, Tyrosine Kinase Inhibitors

2) By Chemotherapy: Platinum-Based chemotherapy, Anthracyclines, Taxanes, Antimetabolites

3) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs), Luteinizing Hormone-Releasing Hormone (LHRH) Agonists

4) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Monoclonal Antibodies, Adoptive Cell Transfer (ACT)

What Current And Upcoming Trends Are Shaping The Breast Cancer Gene (BRCA) Mutations Treatment Market?

Leading companies in the breast cancer gene (BRCA) mutation treatment market are concentrating on developing advanced solutions, such as adjuvant treatment, to improve therapeutic and patient outcomes. Adjuvant treatment is a supplementary therapy given after the primary treatment to eliminate any remaining cancer cells and reduce the likelihood of recurrence, thereby helping to enhance overall treatment success and extend patient survival. For instance, in August 2022, AstraZeneca plc, a UK-based biotechnology company, and Merck & Co., Inc., a US-based pharmaceutical company, launched LYNPARZA (olaparib). This product received European Commission approval for adult patients with germline BRCA-mutated, HER2-negative high-risk early breast cancer. This authorization allows LYNPARZA to be administered as monotherapy or in conjunction with endocrine therapy for patients who have previously undergone neoadjuvant or adjuvant chemotherapy. The approval stemmed from results of the phase 3 OlympiA trial, which demonstrated a significant improvement in invasive disease-free survival and overall survival, substantially decreasing the risk of breast cancer recurrence or death.

Who Are The Primary Market Leaders In The Breast Cancer Gene (BRCA) Mutations Treatment Market?

Major companies operating in the breast cancer gene (BRCA) mutations treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Thermo Fisher Scientific Inc., AstraZeneca PLC, Novartis AG, GSK plc, Janssen Biotech Inc., Astellas Pharma Inc., Agilent Technologies Inc., Genentech Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Invitae Corporation, Guardant Health Inc., Clovis Oncology Inc., Owkin Inc., Allarity Therapeutics Inc., VBL Therapeutics.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/breast-cancer-gene-brca-mutations-treatment-global-market-report

How Do Regional Dynamics Influence The Breast Cancer Gene (BRCA) Mutations Treatment Market Performance?

North America was the largest region in the breast cancer gene (BRCA) mutations treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer gene (BRCA) mutations treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=27231&type=smp

Browse Through More Reports Similar to the Global Breast Cancer Gene (BRCA) Mutations Treatment Market 2025, By The Business Research Company

Converted Paper Products Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/converted-paper-products-global-market-report

Concrete Materials Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/concrete-materials-global-market-report

Cement And Concrete Products Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cement-and-concrete-products-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The Breast Cancer Gene (BRCA) Mutations Treatment Market Size Likely To Evolve From 2025 Through 2034?

The market for treating breast cancer gene (BRCA) mutations has experienced significant expansion recently. Its value is projected to increase from $4.67 billion in 2024 to $5.01 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.4%. This historical growth can be linked to factors such as the expanded access to genetic testing, increased public and private investment in cancer research, a growing need for tailored medical treatments, wider acceptance of preventative health strategies, and a rise in at-risk individuals participating in screening programs.

The breast cancer gene (BRCA) mutations treatment market is anticipated to experience substantial growth over the next few years. It is projected to expand to $6.56 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 7.0%. This growth during the forecast period can be attributed to the increasing integration of genetic testing into insurance coverage, a growing demand for companion diagnostics, a heightened focus on hereditary cancer screening programs, an increase in clinical trials targeting BRCA-related cancers, and the rising adoption of risk-reducing surgical procedures. Prominent trends within the forecast period involve advancements in gene editing technologies, innovations in non-invasive diagnostic techniques, the integration of AI and machine learning in genetic risk assessment, further developments in liquid biopsy applications for BRCA-related cancers, and the emergence of innovative personalized treatment algorithms.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27231&type=smp

What Are The Main Drivers Boosting The Breast Cancer Gene (BRCA) Mutations Treatment Industry’s Expansion?

The future expansion of the breast cancer gene (BRCA) mutation treatment market is anticipated, driven by the growing need for targeted therapies. These medical interventions are designed to precisely attack cancer cells by concentrating on specific genetic mutations or proteins that contribute to tumor development. The increasing preference for targeted therapies stems largely from their capacity to pinpoint and attack disease-causing cells or molecules, thereby reducing harm to healthy tissues. This leads to enhanced treatment efficacy and a reduction in adverse effects when contrasted with conventional treatments. For breast cancer gene (BRCA) mutations, targeted therapies provide crucial support through precision medicines that directly address the underlying genetic changes causing the condition, thus enhancing patient outcomes and mitigating unwanted side effects. An illustration of this trend is seen in a report from the American Society of Gene & Cell Therapy (ASGCT), a US-based professional organization, published in July 2023. This report noted that by the close of Q1 2023, there were 247 gene therapies in Phase II, a figure that subsequently increased by 5% to reach 260 by the end of Q2 2023. Consequently, the expanding need for targeted therapies is a key factor propelling the expansion of the breast cancer gene (BRCA) mutation treatment market.

What Are The Leading Segments Analyzed In The Breast Cancer Gene (BRCA) Mutations Treatment Market?

The breast cancer gene (BRCA) mutations treatment market covered in this report is segmented

1) By Treatment Type: Targeted Therapies, Chemotherapy, Hormonal Therapy, Immunotherapy

2) By Indication: Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer

3) By Administration Route: Oral, Intravenous, Subcutaneous

4) By End-User: Hospitals, Clinics, Cancer Specialty Clinics

Subsegments:

1) By Targeted Therapies: Poly (ADP-Ribose) Polymerase Inhibitors, Mammalian Target Of Rapamycin Inhibitors, Cyclin-Dependent Kinase 4 And 6 Inhibitors, Tyrosine Kinase Inhibitors

2) By Chemotherapy: Platinum-Based chemotherapy, Anthracyclines, Taxanes, Antimetabolites

3) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs), Luteinizing Hormone-Releasing Hormone (LHRH) Agonists

4) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Monoclonal Antibodies, Adoptive Cell Transfer (ACT)

What Key Innovation Trends Are Fueling Advancements In The Breast Cancer Gene (BRCA) Mutations Treatment Market?

Leading companies within the breast cancer gene (BRCA) mutation treatment market are prioritizing the development of advanced solutions, such as adjuvant treatment, to enhance therapeutic and patient outcomes. Adjuvant treatment is a supplemental therapy administered after the primary treatment to eradicate any remaining cancer cells and mitigate the risk of recurrence, thereby improving overall treatment success and extending patient survival. For instance, in August 2022, AstraZeneca plc, a UK-based biotechnology company, and Merck & Co., Inc., a US-based pharmaceutical company, introduced LYNPARZA (olaparib), which secured European Commission approval for adult patients with germline BRCA-mutated, HER2-negative high-risk early breast cancer. This approval enables LYNPARZA to be utilized as monotherapy or in combination with endocrine therapy for patients who have previously received neoadjuvant or adjuvant chemotherapy. The approval was granted based on findings from the phase 3 OlympiA trial, which showed a significant improvement in invasive disease-free survival and overall survival, considerably lowering the risk of breast cancer recurrence or death.

Which Key Market Players Are Investing In Expansion And Innovation Of Breast Cancer Gene (BRCA) Mutations Treatment Market?

Major companies operating in the breast cancer gene (BRCA) mutations treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Thermo Fisher Scientific Inc., AstraZeneca PLC, Novartis AG, GSK plc, Janssen Biotech Inc., Astellas Pharma Inc., Agilent Technologies Inc., Genentech Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Invitae Corporation, Guardant Health Inc., Clovis Oncology Inc., Owkin Inc., Allarity Therapeutics Inc., VBL Therapeutics.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/breast-cancer-gene-brca-mutations-treatment-global-market-report

How Is Breast Cancer Gene (BRCA) Mutations Treatment Market Demand Varying Across Different Regions?

North America was the largest region in the breast cancer gene (BRCA) mutations treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer gene (BRCA) mutations treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Breast Cancer Gene (BRCA) Mutations Treatment Market Report:

https://www.thebusinessresearchcompany.com/customise?id=27231&type=smp

Browse Through More Reports Similar to the Global Breast Cancer Gene (BRCA) Mutations Treatment Market 2025, By The Business Research Company

Converted Paper Products Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/converted-paper-products-global-market-report

Decorative Concrete Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/decorative-concrete-global-market-report

Concrete Materials Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/concrete-materials-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only._x000D_

_x000D_

#What Is the Estimated Industry Valuation for the Breast Cancer Gene (BRCA) Mutations Treatment Sector?#_x000D_

Over the years, the market size for the treatment of mutations in the breast cancer gene (BRCA) has exhibited robust growth. It’s projected to escalate from $4.67 billion in 2024 to $5.01 billion in 2025, with a compound annual growth rate (CAGR) of 7.4%. The growth during the historical period can be owed to several factors. These include the increasing accessibility of genetic testing, enhanced government and private support for oncology research, growing need for personalized medicine, increased acceptance of preventive healthcare measures, and a rise in the number of at-risk population opting for screening._x000D_

_x000D_

The market size for the treatment of breast cancer gene (BRCA) mutations is anticipated to expand considerably in the coming years. Projected growth is a compound annual growth rate (CAGR) of 7.0%, reaching $6.56 billion in value by 2029. The factors driving this projected expansion over the forecast period include increased integration of genetic testing in insurance plans, a surging demand for companion diagnostics, a greater emphasis on screening programs for hereditary cancer, a rise in clinical trials specific to BRCA-related cancers, and growing adoption of preventive surgery procedures. Key trends for this period include advancements in gene editing technology, novel non-invasive diagnostic methods, use of artificial intelligence and machine learning in genetic risk analysis, progress in liquid biopsy applications for BRCA-linked cancers, and innovative personalized treatment algorithms._x000D_

_x000D_

#Download The Free Sample Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=27231&type=smp_x000D_

_x000D_

#What Forces Are Driving The Growth Of The Breast Cancer Gene (BRCA) Mutations Treatment Market?#_x000D_

The growth of the breast cancer gene (BRCA) mutation treatment market is anticipated to be driven by the escalating demand for targeted therapies. These therapies are unique medical treatments that directly target cancer cells by focusing on the genetic mutations or proteins that aid cancer growth. The increased demand for such therapies comes from their unique ability to precisely target the cells or molecules that cause diseases, thereby reducing harm to healthy tissues. Their precision results in enhanced effectiveness of treatment and lesser side effects in comparison to conventional therapies. In the context of breast cancer gene (BRCA) mutations, targeted therapies facilitate the provision of precision medicines tailored to tackle the specific genetic variations fueling the disease. This results in better treatment outcomes and lesser unnecessary side effects. For example, a report published in July 2023 by the American Society of Gene & Cell Therapy (ASGCT), a professional membership organization based in the US, revealed that at the end of Q1 2023, there were 247 gene therapies in Phase II. This number increased by 5% to reach 260 by the end of Q2 2023. Thus, the growing demand for targeted therapies serves as a key driver for the growth of the breast cancer gene (BRCA) mutation treatment market._x000D_

_x000D_

#How Is The Breast Cancer Gene (BRCA) Mutations Treatment Industry Segmented Across Key Parameters?#_x000D_

The breast cancer gene (BRCA) mutations treatment market covered in this report is segmented_x000D_

_x000D_

1) By Treatment Type: Targeted Therapies, Chemotherapy, Hormonal Therapy, Immunotherapy_x000D_

2) By Indication: Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer_x000D_

3) By Administration Route: Oral, Intravenous, Subcutaneous_x000D_

4) By End-User: Hospitals, Clinics, Cancer Specialty Clinics_x000D_

_x000D_

Subsegments:_x000D_

1) By Targeted Therapies: Poly (ADP-Ribose) Polymerase Inhibitors, Mammalian Target Of Rapamycin Inhibitors, Cyclin-Dependent Kinase 4 And 6 Inhibitors, Tyrosine Kinase Inhibitors_x000D_

2) By Chemotherapy: Platinum-Based chemotherapy, Anthracyclines, Taxanes, Antimetabolites_x000D_

3) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs), Luteinizing Hormone-Releasing Hormone (LHRH) Agonists_x000D_

4) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Monoclonal Antibodies, Adoptive Cell Transfer (ACT)_x000D_

_x000D_

#What Notable Trends Are Shaping The Direction Of The Breast Cancer Gene (BRCA) Mutations Treatment Market?#_x000D_

Leading entities in the BRCA (breast cancer gene) mutation treatment market are concentrating their efforts on the advancement of superior solutions, including adjuvant therapy, with an aim to boost treatment efficacy and augment patient results. This adjuvant procedure is an additional therapy applied after the principal treatment to eliminate any residual cancer cells, reducing the possibility of recurrence and thereby improving overall therapy performance and patient survival rates. For example, AstraZeneca plc, a biotechnology enterprise based in the UK, alongside Merck & Co., Inc., a pharmaceutical company in the US, introduced LYNPARZA (olaparib) in August 2022. The European Commission approved this for adult patients with germline BRCA mutations, HER2-negative high-risk initial-stage breast cancer. LYNPARZA can thus be used as a single treatment or combined with endocrine therapy for patients who have undergone prior neoadjuvant or adjuvant chemotherapy. This approval was achieved based on the phase 3 OlympiA trial’s results, which revealed a major enhancement in disease-free and overall survival, significantly diminishing the threat of breast cancer recurrence or death._x000D_

_x000D_

#Which Companies Currently Dominate The Competitive Landscape In The Breast Cancer Gene (BRCA) Mutations Treatment Industry?#_x000D_

Major companies operating in the breast cancer gene (BRCA) mutations treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Thermo Fisher Scientific Inc., AstraZeneca PLC, Novartis AG, GSK plc, Janssen Biotech Inc., Astellas Pharma Inc., Agilent Technologies Inc., Genentech Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Invitae Corporation, Guardant Health Inc., Clovis Oncology Inc., Owkin Inc., Allarity Therapeutics Inc., VBL Therapeutics. _x000D_

_x000D_

#Get The Full Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/breast-cancer-gene-brca-mutations-treatment-global-market-report_x000D_

_x000D_

#Which Geographic Regions Are Driving Demand In The Breast Cancer Gene (BRCA) Mutations Treatment Market?#_x000D_

North America was the largest region in the breast cancer gene (BRCA) mutations treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer gene (BRCA) mutations treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request For A Customized Report:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=27231&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model